Business
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
SAN JOSE, Calif., March 11, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., March 11, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO of Anixa, will participate in the 24th Annual World Vaccine Congress being held April 1-4, 2024. Dr. Kumar will speak on Thursday, April 4th, in the Cancer Immunotherapy Track.\n\n \n \n \n \n \n \n\n \nDetails are as follows:\nLocation:\nWalter E. Washington Convention Center, Washington, D.C.\nTickets:\nVisit the conference website.\nSession:\nApril 4, 2024 | Cancer Immunotherapy\nEmerging Targets & Strategies track\n11:45 a.m.: \"Early-stage clinical results from a novel preventative breast cancer vaccine.\"\nDr. Kumar will speak about positive interim results from the Phase 1 clinical trial of Anixa's breast cancer vaccine. In the most recent data, 75% of women showed immune responses, with responses observed at all dose levels. The vaccine is designed to direct the immune system to destroy triple negative breast cancer (TNBC) cancer cells through a mechanism that has never previously been utilized for cancer vaccine development. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.\nDr. Kumar will be available during the Congress for one-on-one meetings.\nThe World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meetings of their kind across the globe since 2000. The World Vaccine Congress Washington 2024 will host 4,000+ attendees, 450+ speakers, and 350+ exhibitors.\nAbout Anixa Biosciences, Inc.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian canc...